GALT
$9.16
Galectin Therapeutic
$.41
4.69%
GALT
Earnings Whisper ®
N/A
2nd Quarter June 2018
Consensus:  ($0.14)
Revenue:  N/A
Friday
Aug 10
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when GALT reports earnings?
Beat
Meet
Miss

Where is GALT's stock price going from here?
Up
Flat
Down
Stock chart of GALT
Analysts
Summary of analysts' recommendations for GALT
Score
Grade
Pivots
Resistance
$10.30
$9.89
$9.53

$9.12

Support
$8.76
$8.35
$7.99
Tweet
Growth
Description
Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts.